What is tirzepatide?
Tirzepatide activates two gut-hormone receptors at once — GLP-1 and GIP — which is why researchers call it a dual agonist and why it has drawn so much attention in weight and metabolic research.
This page collects everything we've written about it: how it works, dosing and titration, side effects, comparisons with semaglutide, and what compounded tirzepatide involves. Compounded tirzepatide is available only by prescription; a licensed provider reviews every request, and not everyone qualifies. Start with the mechanism article if you're new — the rest builds on it.
100 articles on this topic
-
Tirzepatide News Update: September 2026
The month's biggest change is narrow but important: Mounjaro gained a cardiovascular-risk indication for certain adults with type 2 diabetes. Here is what else changed—and what did not.
-
Does Medicare Cover GLP-1 for Weight Loss? It Can
Some Medicare patients now qualify for a $50 monthly GLP-1 prescription. The Bridge has specific product and health requirements, and compounded prescriptions are outside it.
-
Semaglutide Pronunciation: How to Say It
Semaglutide is pronounced sem-a-GLOO-tide. The middle is easier once you know where the stress goes and why several related medicine names share the same ending.
-
Tesamorelin vs Tirzepatide: Which Fits Which Goal?
Tesamorelin and tirzepatide can both change fat-related measures, but they answer different clinical questions. One has narrow evidence for deep abdominal fat in adults with HIV lipodystrophy; the other was studied for total body weight.
-
503B Bulks List GLP-1: Still a Proposal
FDA proposes leaving three GLP-1 ingredients off the 503B bulks list. Comments closed July 30; patient-specific prescriptions follow separate rules.
-
Tirzepatide Meal Plan: Small Meals, Protein First
A useful tirzepatide meal plan is smaller and steadier: protein first, produce and fiber as tolerated, and fluids between meals. It should bend around appetite and side effects, not force a calorie target.
-
Novo Nordisk Lilly Lawsuit: What It Doesn't Decide
The fight is about how Zepbound ads frame a head-to-head trial after a higher Wegovy dose reached the market. It is not a court verdict on which medication is better for you.
-
Semaglutide News Update: September 2026
New child-trial results, heart-failure guidance, access changes and a June label update—what each means for a semaglutide prescription.
-
Compounded Tirzepatide Side Effects: What Changes?
Most side effects come from tirzepatide itself. Compounding can add a second layer of risk through concentration, measurement, added ingredients, sterility, and potency.
-
Tirzepatide for Seniors: What New 2026 Data Show
Age 65 alone does not rule out tirzepatide. New 2026 research is reassuring, but adults over 75 remain underrepresented and the safest decision turns on muscle reserve, hydration, kidney health and other medicines.
-
Retatrutide Early Access Is Real—and Very Limited
Retatrutide early access now exists through a narrow, doctor-led program. It is not a public prescription route, a sale, or an approval.
-
Tirzepatide Before and After: An Honest Timeline
Tirzepatide before and after photos can't tell you what caused a change. The trials give a more useful timeline: early appetite shifts, months of gradual change, and a later plateau that varies widely.
-
Tirzepatide and Blood Pressure: Does It Lower It?
Yes—blood pressure often falls during tirzepatide treatment, mostly alongside weight loss. That can be welcome, but it also means people taking blood-pressure medicine may need closer review if lightheadedness starts.
-
Tirzepatide and Gallbladder Risk: Small but Real
Gallstones turn up in about 1 in 100 people on tirzepatide in the trials — barely above placebo — but inflamed gallbladders are three and a half times as common. Here is why, and the pain pattern that means call someone today.
-
Tirzepatide and Menopause: What the Evidence Says
Menopause does not appear to stop tirzepatide from working for weight management. The useful question is whether it fits the whole health picture, including sleep, muscle, bone and any hormone therapy already in use.
-
Tirzepatide Psoriasis Data Don’t Make It a Treatment
New 52-week data found better skin and joint outcomes when branded tirzepatide was added to Taltz in adults with psoriatic disease and obesity. That supports treating two linked conditions together—not using tirzepatide alone for psoriasis.
-
Compounded Medication Recall: Check the Lot
A recall usually applies to one pharmacy, one preparation and specific lot numbers—not every compounded medication. Here is how to check a vial and reach the people responsible for it.
-
Tirzepatide 3 Month Supply: What You Get
Three months usually means a series of monthly dose packages, not one vial kept open for 90 days. The prescription, storage dates, and billing period each answer a different part of the question.
-
Semaglutide and Tirzepatide Together? Usually No
Semaglutide and tirzepatide together are not a recommended combination. Both reach the same GLP-1 pathway; a switch should be planned as one treatment replacing the other, with timing and dose set by a prescriber.
-
GLP-1 Heart Failure Guidelines Changed in 2026
Europe's 2026 ESC guideline now says semaglutide or tirzepatide should be considered for a narrow group with symptomatic heart failure and obesity. It is an option for a cardiologist to weigh, not a direction to start either drug on your own.
Page 2 of 5 · 100 articles